`
`CBM2016-00091
`U.S. Patent No. 9,037,502
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________
`
`FACEBOOK, INC. and INSTAGRAM LLC,
`PETITIONERS
`
`V.
`
`SKKY, LLC
`PATENT OWNER
`_____________________
`
`CASE CBM2016-00091
`PATENT 9,037,502
`
`PATENT OWNER’S RESPONSE TO PETITIONERS’ SUPPLEMENTAL
`BRIEF REGARDING REQUEST FOR REHEARING
`
`
`
`CBM2016-00091
`U.S. Patent No. 9,037,502
`
`Rembrandt Wireless Techs., LP v. Samsung Elecs. Co., No. 2016-1729, 2017
`
`U.S. LEXIS 6502 (Fed. Cir. April 17, 2017), is irrelevant to this matter. So, too,
`
`are Petitioners’ arguments submitted in their supplemental briefing. Petitioners
`
`seek to expand the narrow holding of Rembrandt to upend the Board’s well-
`
`reasoned institution decision and supplant an established trend in proceedings
`
`before the Board. If the Board adopts Petitioners’ position, not only would the
`
`Board promote inefficiencies in post-grant review, the Board would be
`
`contravening the explicit regulatory language governing CBM review. For these
`
`reasons, the Board should deny Petitioners’ request for rehearing.
`
`
`
`First, the rationale in Rembrandt is inapplicable to the case at hand. Indeed,
`
`the Rembrandt decision does not reference CBM proceedings, as Petitioners’
`
`counsel admitted during the April 24, 2017 teleconference. Rather, the Rembrandt
`
`decision is concerned specifically with the marking requirement of 28 U.S.C. §
`
`287. Rembrandt, 2017 U.S LEXIS 650 at *23. In particular, the Board premised its
`
`decision on public notice function of patent marking. Id. at *25.
`
`
`
`Petitioners’ briefing omits important background information leading to the
`
`Rembrandt decision. In the district court proceedings, Rembrandt asserted a
`
`number of claims against Samsung, including claim 40. Id. Rembrandt, however,
`
`failed to require its licensees to mark products embodying claim 40. Id. Shortly
`
`before trial, based on the failure to mark, Samsung moved to limit Rembrandt’s
`
`
`
`1
`
`
`
`CBM2016-00091
`U.S. Patent No. 9,037,502
`damages to the period of time beginning when Samsung received notice of
`
`infringement through Rembrandt’s complaint. Id. To avoid this limitation, eight
`
`days later, Rembrandt disclaimed claim 40. Id. at *23-24. The district court then
`
`denied Samsung’s motion based on Rembrandt’s disclaimer. Id. at *24.
`
`
`
`The Federal Circuit vacated and remanded the district court’s denial,
`
`emphasizing the purpose of the marking statute—to protect the public from
`
`liability for unknown infringement. Id. at *25. Because the purpose of marking is
`
`to provide public notice, the Court reasoned that it was “irreconcilable” for
`
`disclaimer to extinguish the right of the public to utilize unmarked features of a
`
`product until receiving notice. Id. Protecting the public’s rights was central to the
`
`decision, as reflected in the Court’s narrow holding: “the marking statute’s focus is
`
`not only the rights of the patentee, but the rights of the public . . . we hold that
`
`disclaimer cannot serve to retroactively dissolve the § 287(a) marking requirement
`
`for a patentee to collect pre-notice damages.” Id. at *27. There is no reason to
`
`globally expand this holding, especially given that the Court did not discuss post-
`
`grant review proceedings in its decision.
`
`
`
`In contrast to the marking statute in Rembrandt, the regulations governing
`
`post-grant review contemplate disclaimer after a petition is filed. 37 C.F.R. §
`
`42.207 relates to a patent owner’s preliminary response to a petition. The
`
`regulation is clear that “[t]he patent owner may file a statutory disclaimer” of “one
`
`
`
`2
`
`
`
`CBM2016-00091
`U.S. Patent No. 9,037,502
`or more claims in the patent” and that “[n]o post-grant review will be instituted
`
`based on disclaimed claims.” 37 C.F.R. § 42.207(e). In other words, this exact
`
`situation was anticipated and disclaimer of some or all claims was an approved
`
`response to a petition for post-grant review. The Board’s decision is thus aligned
`
`with the purposes of post-grant review and should stand.
`
`
`
`Petitioners’ argument that 37 C.F.R. § 42.207(e) only applies to review of the
`
`disclaimed claims is unavailing. Nothing in the regulatory language or commentary
`
`to the same limits the application of 207(e) only to disclaimed claims. Rather, the
`
`plain language is clear that institution will not be based on the disclaimed claim.
`
`This, however, is exactly what Petitioners seek. Having failed to meet their burden
`
`with regards to the remaining claims, Petitioners seek reconsideration and
`
`institution of CBM review based entirely on the disclaimed claims. In so doing,
`
`Petitioners seek to directly contradict the plain language of the regulation. Such
`
`relief must be denied.
`
`
`
`Further, it is unclear which, if any, of the public’s rights are extinguished by
`
`the Board’s decision. Petitioners seem to rely on the right of an alleged infringer to
`
`petition for CBM review after being sued for patent infringement. Even accepting
`
`that right as a public right, Petitioners only have a right to petition for institution of
`
`CBM review—there is no right to institution based on that petition. Here,
`
`Petitioners exercised their right when they filed their Petition on June 15, 2016.
`
`
`
`3
`
`
`
`CBM2016-00091
`U.S. Patent No. 9,037,502
`Patent Owner’s subsequent disclaimer did not, and could not, retroactively
`
`eliminate that right—Petitioners already utilized it. This is a far cry from the
`
`Rembrandt decision, where Samsung’s right to practice unmarked features was
`
`snuffed out on the eve of trial, exposing Samsung to a significantly expanded
`
`damages period. Petitioners are not similarly situated and instead try to force the
`
`round peg of Rembrandt into the square hole of this case. Since Patent Owner’s
`
`disclaimer did not “relinquish the rights” of Petitioners, Rembrandt’s holding is
`
`irrelevant to these proceedings.
`
`
`
` Finally, Petitioners have no answer to the Board’s well-reasoned institution
`
`decision. Paper 7. In its decision, the Board recognized that the majority of panels
`
`confronted with the disclaimer issue treat the disclaimed claims as having never
`
`existed. Id. at 8-9. This approach is consistent with Federal Circuit precedent and
`
`regulatory scheme forming the basis of post-grant review. Petitioners cite to
`
`nothing in Rembrandt justifying altering the Board’s determination. Instead,
`
`Petitioners misapply Rembrandt in an attempt to obtain a second bite at the apple.
`
`Petitioners similarly reinterpret the Board’s analysis of Genetics Inst., LLC v.
`
`Novartis Vaccines & Diagnostics, Inc., 655 F.3d 1291 (Fed. Cir. 2011), Albert v.
`
`Kevex Corp., 729 F.2d 757 (Fed. Cir. 1984), and Guinn v. Kopf, 96 F.3d 1419,
`
`1422 (Fed. Cir. 1996) to find support for their position. Despite these
`
`misapplications, Petitioners cite to nothing in any of the above cases supporting
`
`
`
`4
`
`
`
`CBM2016-00091
`U.S. Patent No. 9,037,502
`rehearing. The Board may only institute CBM review “for a patent that is a CBM
`
`patent.” J.P. Morgan Chase & Co. v. Intellectual Ventures II, CBM2014-00160,
`
`Paper 11 at 5 (PTAB Jan. 29, 2015). Here, the ’502 patent is not a CBM patent.
`
`Petitioners’ request should be denied.
`
`
`
`Petitioners are grasping at straws. Having failed to demonstrate that the
`
`remaining claims are patent ineligible, Petitioners seek to resurrect the disclaimed
`
`claims in order to reargue their position. This is an inefficient use of the parties’,
`
`and the Board’s, valuable time. The disclaimed claims no longer exist and can no
`
`longer be asserted against Petitioners. These claims, in turn, cannot serve as the
`
`basis of institution of post-grant review. This is the process working as intended—
`
`post-grant review narrowed the scope of the asserted patent, in this case because
`
`Patent Owner disclaimed a number of claims. In turn, these claims cannot form the
`
`basis of a decision to institute CBM proceedings. There is no error here, there is no
`
`new precedent, and there is nothing to reconsider. Accordingly, the Board should
`
`deny Petitioners’ request for rehearing.
`
`
`Dated: May 8, 2017
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Ryan M. Schultz/
`Ryan M. Schultz
`Registration No. 65,134
`Andrew J. Kabat
`Registration No. 71,252
`Attorneys for Patent Owner
`Robins Kaplan LLP
`
`5
`
`
`
`CBM2016-00091
`U.S. Patent No. 9,037,502
`
`2800 LaSalle Plaza
`800 LaSalle Ave
`Minneapolis, MN 55401
`
`
`
`6
`
`
`
`
`
`
`
`CBM2016-00091
`U.S. Patent No. 9,037,502
`
`
`CERTIFICATE OF SERVICE
`
`
`
`I hereby certify that on this May 8, 2017, a copy of PATENT OWNER’S
`
`RESPONSE TO PETITIONERS’ SUPPLEMENTAL BRIEF REGARDING
`
`REQUEST FOR REHEARING has been served in their entirety by electronic mail
`
`to Petitioners:
`
`hkeefe@cooley.com
`amace@cooley.com
`zpatdcdocketing@cooley.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Ryan M. Schultz/
`
`Ryan M. Schultz
`Registration No. 65,134
`Andrew J. Kabat
`Registration No. 71,252
`
`7
`
`



